Orion OYJ (OTCMKTS:ORINY) Reaches New 12-Month High – Still a Buy?

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY)’s share price reached a new 52-week high during trading on Thursday. The stock traded as high as $56.26 and last traded at $56.26, with a volume of 223 shares. The stock had previously closed at $54.7750.

Analysts Set New Price Targets

Separately, Jefferies Financial Group upgraded shares of Orion OYJ from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy”.

Orion OYJ Trading Up 3.4%

The company has a quick ratio of 1.48, a current ratio of 2.64 and a debt-to-equity ratio of 0.08. The stock’s 50 day moving average is $47.94 and its 200-day moving average is $41.63. The company has a market cap of $16.41 billion, a PE ratio of 21.46 and a beta of 0.07.

Orion OYJ (OTCMKTS:ORINY) last issued its quarterly earnings data on Wednesday, October 28th. The company reported $0.68 earnings per share for the quarter. The company had revenue of $623.96 million for the quarter. Orion OYJ had a return on equity of 54.09% and a net margin of 30.25%.

Orion OYJ Company Profile

Orion Oyj, also known as Orion Corporation, is a Finnish pharmaceutical company that develops, manufactures and markets human and veterinary medicines. Its portfolio includes prescription medicines, over-the-counter products, generic pharmaceuticals and active pharmaceutical ingredients.

The company focuses on several therapeutic areas, including central nervous system disorders, oncology, respiratory diseases, pain management and veterinary medicine. Orion is particularly recognized for treatments related to Parkinson’s disease, as well as its Easyhaler line of inhaled medicines for respiratory conditions.

Founded in Finland in 1917, Orion is headquartered in Espoo.